Eli Lilly (NYSE:LLY) stock rose 13% overnight after it beat analyst estimates and raised guidance. The company’s GLP-1 drugs for diabetes and weight loss, Zepbound and Mounjaro, propelled the results.The company reported net income of $2.97 billion, $3.28 per share fully diluted, on revenue of $11.3 billion. Lilly also raised its full-year revenue guidance to $45.4 billion-$46.6 billion and earnings per share guidance to $15.10-$15.40 per share. The market responded as if Lilly was selling artificial intell ...

Eli Lilly (LLY) came out with quarterly earnings of $3.92 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 48.48%. A quarter ago, it was expected that this drugmaker would post earnings of $2.53 per share when it actually produced earnings of $2.58, delivering a surprise of 1.98%.Over the last four quarters, the company has su ...

Key TakeawaysEli Lilly shares soared Thursday after the Mounjaro and Zepbound maker posted better second-quarter earnings than expected on soaring sales for its weight-loss drugs Mounjaro and Zepbound.The company also lifted its full-year revenue and profit guidance as its supply of weight-loss drugs improves.Eli Lilly shares jumped 12% before the opening bell and are up nearly 50% this year. Eli Lilly (LLY) shares surged higher in premarket trading Thursday after the drugmaker's second-quarter earnings cam ...

ToplinePharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts’ expectations in the face of growing competition in the lucrative weight loss drug market as it struggles to boost supplies and tackle shortages.Eli Lilly has struggled to keep up with demand for its weight loss and diabetes drug tirzepatide.Getty Images Key FactsEli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for the second quarter of 2 ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Aug. 8, 2024 For Release: Immediately Refer to: Jordan Bishop; jordan.bishop@lilly.com; (317) 374-1878 (Media) Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors) Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion • Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%. Excluding the sale of rights for Baqsimi, non-in ...

MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs proudly unveils LLYX, the world's first single-stock leveraged ETF for Eli Lilly. LLYX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Eli Lilly without the need for a margin account, providing a unique tool for tactical traders. LLYX does not invest directly in Eli Lilly and has a higher degree of risk due to tracking a single stock. Eli Lilly and Company, established in 1876 and headquartered in India ...

News from a competitor gave investors an unwelcome dose of reality.Shares of Eli Lilly (LLY -2.65%) fell 20% in July, according to data from S&P Global Market Intelligence. The pharmaceutical stock tumbled after one of the company's competitors announced promising clinical trial news on an obesity drug. Lilly has two obesity products that are powering sales right now, and it could lose market share ahead of schedule if any of its rivals push smoothly through development.Unwelcome news from a key competitorO ...

Eli Lilly and Co LLY will be reporting its second-quarter earnings on Thursday. Wall Street expects $2.70 in EPS and $9.9 billion in revenues as the company reports before market hours.The stock is up 69% over the past year, and has gained 30% YTD.Let’s look at what the charts indicate for Eli Lilly stock, and how the stock currently maps against Wall Street estimates.Eli Lilly Stock Faced Potential Downside Risk Ahead Of Q2 Earnings…Eli Lilly’s stock is currently exhibiting a strongly bearish trend, as the ...

Eli Lilly and Company LLY is expected to release earnings results for its second quarter, before the opening bell on Thursday, Aug. 8.Analysts expect the Indianapolis-based company to report quarterly earnings at $2.60 per share, up from $2.11 per share in the year-ago period. Eli Lilly is projected to post revenue of $9.92 billion, compared to $8.31 billion a year earlier, according to data from Benzinga Pro.Some investors may be eyeing potential gains from the company's dividends. Eli Lilly currently has ...